FDMT Stock - 4D Molecular Therapeutics, Inc.
Unlock GoAI Insights for FDMT
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $37,000 | $20.72M | $3.13M | $18.04M | $13.61M |
| Gross Profit | $37,000 | $-76,373,000 | $-77,124,000 | $-43,322,000 | $-39,426,000 |
| Gross Margin | 100.0% | -368.5% | -2464.8% | -240.2% | -289.6% |
| Operating Income | $-187,841,000 | $-112,867,000 | $-110,032,000 | $-71,333,000 | $-56,664,000 |
| Net Income | $-160,868,000 | $-100,837,000 | $-107,494,000 | $-71,317,000 | $-56,693,000 |
| Net Margin | -434778.4% | -486.6% | -3435.4% | -395.4% | -416.5% |
| EPS | $-2.98 | $-2.58 | $-3.12 | $-2.46 | $-2.12 |
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 7th 2025 | Morgan Stanley | Upgrade | Equal Weight | - |
| January 13th 2025 | BMO Capital Markets | Downgrade | Market Perform | $15← $40 |
| November 21st 2024 | Morgan Stanley | Initiation | Underweight | $8 |
| September 23rd 2024 | Cantor Fitzgerald | Downgrade | Neutral | - |
| April 15th 2024 | Barclays | Initiation | Overweight | $459 |
| February 7th 2024 | Goldman | Resumed | Buy | $81 |
| October 26th 2023 | RBC Capital Mkts | Initiation | Outperform | $25 |
| October 24th 2023 | Cantor Fitzgerald | Initiation | Overweight | $32 |
| October 18th 2023 | Leerink Partners | Upgrade | Outperform | $24 |
| July 5th 2023 | Chardan Capital Markets | Initiation | Buy | $30 |
| January 30th 2023 | BMO Capital Markets | Initiation | Outperform | $50 |
| November 18th 2022 | H.C. Wainwright | Initiation | Buy | $36 |
| November 15th 2022 | Goldman | Upgrade | Buy | $68← $12 |
| August 12th 2022 | SVB Leerink | Downgrade | Market Perform | $12 |
| June 22nd 2022 | Jefferies | Initiation | Buy | $22 |
Earnings History & Surprises
FDMTEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Feb 27, 2026 | $-0.53 | — | — | — |
Q4 2025 | Nov 10, 2025 | $-1.02 | $-1.01 | +1.0% | ✓ BEAT |
Q3 2025 | Aug 11, 2025 | $-0.88 | $-0.98 | -11.4% | ✗ MISS |
Q2 2025 | May 8, 2025 | $-0.84 | $-0.86 | -2.4% | ✗ MISS |
Q1 2025 | Feb 28, 2025 | $-0.80 | $-0.90 | -12.5% | ✗ MISS |
Q4 2024 | Nov 13, 2024 | $-0.67 | $-0.79 | -17.9% | ✗ MISS |
Q3 2024 | Aug 8, 2024 | $-0.72 | $-0.63 | +12.5% | ✓ BEAT |
Q2 2024 | May 9, 2024 | $-0.73 | $-0.66 | +9.6% | ✓ BEAT |
Q1 2024 | Feb 29, 2024 | $-0.68 | $-0.77 | -13.2% | ✗ MISS |
Q4 2023 | Nov 9, 2023 | $-0.67 | $-0.24 | +64.2% | ✓ BEAT |
Q3 2023 | Aug 9, 2023 | $-0.77 | $-0.77 | 0.0% | = MET |
Q2 2023 | May 10, 2023 | $-0.88 | $-0.88 | 0.0% | = MET |
Q1 2023 | Mar 15, 2023 | $-0.75 | $-0.84 | -12.0% | ✗ MISS |
Q4 2022 | Nov 8, 2022 | $-0.85 | $-0.79 | +7.1% | ✓ BEAT |
Q3 2022 | Aug 11, 2022 | $-0.78 | $-0.87 | -11.5% | ✗ MISS |
Q2 2022 | May 12, 2022 | $-0.73 | $-0.82 | -12.3% | ✗ MISS |
Q1 2022 | Mar 28, 2022 | $-0.82 | $-0.85 | -3.7% | ✗ MISS |
Q4 2021 | Nov 10, 2021 | $-0.83 | $-0.82 | +1.2% | ✓ BEAT |
Q3 2021 | Aug 12, 2021 | $-0.71 | $-0.28 | +60.6% | ✓ BEAT |
Latest News
Chardan Capital Maintains Buy on 4D Molecular Therapeutics, Maintains $26 Price Target
📈 Positive4D Molecular falls after early-stage trial data for cystic fibrosis therapy
📉 Negative4D Molecular Therapeutics Says Interim Data From 4D-710 Phase 1 AEROW Trial For Cystic Fibrosis Lung Disease Shows Meaningful Lung Function Activity
📈 Positive4D Molecular Therapeutics Has Appointed Kristian Humer As CFO
➖ NeutralRBC Capital Maintains Outperform on 4D Molecular Therapeutics, Raises Price Target to $32
📈 PositiveBarclays Maintains Overweight on 4D Molecular Therapeutics, Lowers Price Target to $33
➖ NeutralChardan Capital Maintains Buy on 4D Molecular Therapeutics, Raises Price Target to $26
📈 Positive4D Molecular Therapeutics Q3 EPS $(1.01) Misses $(0.98) Estimate, Sales $90.000K Miss $287.857K Estimate
📉 Negative4D Molecular Therapeutics shares are trading higher. The company announced the pricing of its $100 million offering.
📈 Positive4D Molecular Therapeutics stock rises after pricing $100M offering
📈 Positive4D Molecular Therapeutics Prices $100M Offering Including 8.4M Common Shares At $10.51 Each And 1.1M Pre-Funded Warrants At $10.5099 Each
➖ NeutralReported Earlier, 4DMT And Otsuka Pharmaceutical Sign $85M Upfront License Deal With Up To $336M In Milestones To Develop And Commercialize 4D-150 Across Asia-Pacific
📈 PositiveRBC Capital Reiterates Outperform on 4D Molecular Therapeutics, Maintains $26 Price Target
📈 PositiveOn Sept 30, 4d Molecular Therapeutics Appointed Ashoo Gupta As Principal Financial Officer Effective Immediately
➖ Neutral4D Molecular Therapeutics Says 4FRONT-1 Phase 3 Trial Enrollment Continues To Exceed Expectations, With Enrollment Completion Now Expected In Q1 2026
📈 PositiveFrequently Asked Questions about FDMT
What is FDMT's current stock price?
What is the analyst price target for FDMT?
What sector is 4D Molecular Therapeutics, Inc. in?
What is FDMT's market cap?
Does FDMT pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to FDMT for comparison